摘要
目的观察化疗交替靶向药物治疗对EGFR突变阳性的晚期非小细胞肺癌患者PFS及OS的影响。方法选取100例EGFR突变阳性的晚期NSCLC患者作为研究对象,将患者分为2组,A组为吉西他滨+顺铂/卡铂化疗交替吉非替尼组,B组为单用吉非替尼组。比较患者治疗过程中的耐受情况、不良反应的发生率和总缓解率(ORR);对比A、B组患者的肿瘤无进展生存期(PFS)、总生存期(OS)和患者生活质量评分(Qo L)。结果 2组患者的不良反应发生率无统计学差异(P>0.05),治疗期间A组5例患者因无法耐受不良反应而退出,B组4例患者退出。A组患者ORR为68.89%,B组ORR为47.86%,差异具有统计学意义(P<0.05)。A组患者的PFS、OS和Qo L高于B组,差异具有统计学意义(P<0.05)。结论化疗交替靶向药物在晚期EGFR突变阳性的NSCLC的治疗中具有显著的临床疗效,值得在临床上进行推广和应用。
Objective To observe the effect of chemotherapy alternately targeted drugs on progression free survival( PFS) and overall survival( OS) in EGFR mutation positive patients with advanced non-small cell lung cancer( NSCLC). Methods 100 cases of EGFR mutation positive patients with advanced NSCLC were chosen as the research object,and were divided into 2 groups,group A received gemcitabine + cisplatin / carboplatin chemotherapy alternated with gefitinib,and group B received the single use of gefitinib. Tolerance,adverse reaction rates and total remission rates( ORR) during the treatment process were compared; PFS,OS and quality of life score( Qo L) were contrasted between group A and B. Results The rates of adverse reactions of the 2 groups showed no statistical difference( P > 0. 05). During the treatment,due to the severity of adverse reaction5 patients in group A quitted,and 4 in group B quitted; ORR of group A was 68. 89%,and that of group B was 47. 86%,there had significant difference( P < 0. 05). PFS,OS and Qo L of patients in group A were higher than those of group B,there had significant difference( P < 0. 05). Conclusion Chemotherapy alternately targeted drugs for EGFR mutation positive patients with advanced NSCLC has significant clinical efficacy,it is worthy of clinical promotion and application.
出处
《实用癌症杂志》
2015年第1期96-98,共3页
The Practical Journal of Cancer
关键词
化疗交替靶向药物
非小细胞肺癌
吉非替尼
PFS
OS
Chemotherapy alternately targeted drug
Non-small cell lung cancer(NSCLC)
Gefitinib
PFS
OS
